Delivered as a Hybrid Event
Main Conference Day 1 - Oct 21, 2025 - JT (Japan Time, GMT+09:00)
- Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
- Tomoyuki Igawa, PhD - Head of Research, Chugai Pharmaceutical Co., Ltd.
- Karen Silence, PhD - Head Preclinical Product Development, Argenx
- Philip Kim, PhD - Professor, University of Toronto & CTO and Co-Founder, Fable Therapeutics
- Fortunato Ferrara, PhD - Vice President, Antibody Discovery, Specifica
This presentation will explore how Adimab has revolutionized antibody discovery, growing from an innovative startup into a leading platform technology company. We will examine key technological breakthroughs in our platform, focusing on synthetic antibody library evolution, advances in multispecific generation, and novel approaches to developability optimization. Join us to learn how Adimab's engineering-driven approach is shaping the future of therapeutics.
- Aaron Sato, PhD - Chief Strategy Officer, Adimab
- Takashi Sato, PhD - Chief Scientist & Technical Architect, Life Science Product Division, Rigaku Corporation
This presentation will explore how Twist Biopharma Solutions leverages data-driven antibody discovery with hyperimmune and humanized mice to maximize hit rates, accelerate timelines, and improve success against even the most challenging oncology targets
- Colby Souders PhD - Chief Scientific Officer, Biopharma VP, Twist Bioscience
- Kevin Fitzgerald, PhD. - Chief Scientific Officer, Epsilogen
- Yasmina Abdiche, PhD - SVP, Exploratory Research, OmniAb
- Adinarayana Kunamneni, PhD - Associate Professor of Medicine, Mayo Clinic
- Wei Yan, PhD - CEO, Sound Biologics
- Keisuke Mitamura - Senior Scientist, Research Division, Kyowa Kirin
In this talk, we present the CHO Edge System, which integrates a glutamine synthetase (GS)-CRISPR knockout CHO host, a hyperactive transposase, libraries of characterized genetic elements to control cellular functions, and computational tools for rational vector design and multi-omics analysis. We present case studies highlighting the impact of these tools to optimize expression for both standard monoclonal and bispecific antibodies.
- Imroz Ghangas - Vice President of Commercial Sales, Asimov